Submitted by Jeffrey Lake on Fri, 10/20/2017 - 9:06am Please indicate your specialization * Oncologist Nurse practitioner in oncology Physician assistant in oncology Specialty pharmacist Radiologist Oncology nurse Genetic counselor Geneticist Pathologist Other, please specify: Please indicate your specialization Other, please specify: What is your preferred method for online learning about recent advances in the management of Breast Cancer * Scientific publications Roundtable/panel discussions by experts in the field Case studies presented by experts in the field Webcasts by experts in the field International congresses highlights Interactive E-learning modules Infographics/visual summaries If you are not able to attend a congress how do you get updated on the information presented there? * Online written congress reports Online expert roundtable congress reports Local/regional meetings with experts that attended the congress Other, please specify: If you are not able to attend a congress how do you get updated on the information presented there? Other, please specify: How aware are you of the current and emerging first-line treatment options for patients with hormone receptor positive breast cancer? * Very aware Aware Reasonably aware Not very aware Not aware How familiar are you with the latest clinical data of emerging therapies (such as PARP-inhibitors) for first-line treatment of hormone receptor positive breast cancer? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How aware are you of the current and emerging treatment options (such as PARP-inhibitors) for patients with gBRCA adjuvant and for gBRCA metastatic breast cancer? * Very aware Aware Reasonably aware Not very aware Not aware How familiar are you with the different mechanisms of action of emerging therapies for gBRCA adjuvant and metastatic breast cancer? * Very well informed Well informed Reasonably informed Poorly informed Not informed How informed are you on the different currently available and emerging agents (such as PARP-inhibitors) with regards to overall survival, durability of response and tolerability of agents for gBRCA adjuvant and metastatic breast cancer? * Very well informed Well informed Reasonably informed Poorly informed Not informed How familiar are you with the available tests, assays and multi-gene panels and companion diagnostics in choosing the best therapy for patients with breast cancer? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How familiar are you with the identification of eligible patients with gBRCA adjuvant and metastatic breast cancer to start treatment with emerging therapies (such as PARP-inhibitors, when approved)? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How aware are you of the current and emerging (such as PARP-inhibitors) first- and second line treatment options for patients with Breast Cancer Associated mutated (BRCAm) ovarian cancer? * Very aware Aware Reasonably aware Not very aware Not aware How aware are you of the current and emerging (such as PARP-inhibitors) treatment options for patients with advanced germline Breast Cancer Associated mutated (gBRCA) ovarian cancer? * Very aware Aware Reasonably aware Not very aware Not aware How familiar are you with the available tests, assays and multi-gene panels and companion diagnostics in choosing the best therapy for patients with BRCAm and gBRCA ovarian cancer? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How informed are you about the latest clinical trial data on emerging targeted therapies (such as PARP-inhibitors) for BRCAm and gBRCA ovarian cancer? * Very well informed Well informed Reasonably informed Poorly informed Not informed How familiar are you with the difference in the safety profiles between current treatment options and emerging targeted therapies (such as PARP-inhibitors) for patients with BRCAm and gBRCA ovarian cancer? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How familiar are you with the identification of eligible patients with BRCAm and gBRCA ovarian cancer to start treatment with emerging therapies (such as PARP-inhibitors, when a * Very familiar Familiar Reasonably familiar Not very familiar Not familiar If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following: First Name: Last Name: Email: Leave this field blank
